Novo Nordisk A/S (NVO) Stock Price, News & Analysis

Company Overview

Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders.

Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies. Novo Nordisk’s products are marketed in numerous countries worldwide and are supported by research, manufacturing and commercial operations across multiple regions.

Novo Nordisk was formed through the 1989 merger of Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium, two Danish companies that had developed insulin treatments in the early twentieth century. Maziar Mike Doustdar serves as president and chief executive officer, while Helge Lund serves as chair of the board of directors.

Key Stats

• Today's Range: $42.72 to $43.50
• 50-Day Range: $43.03 to $51.56
• 52-Week Range: $35.12 to $64.16
• Volume: 11.00 million shs
• Average Volume: 17.18 million shs
• Market Capitalization: $192.15 billion
• P/E Ratio: 10.52
• Dividend Yield: 1.91%
• Price Target: $64.94
• Consensus Rating: Hold

Novo Nordisk A/S Stock Analysis - MarketRank™

Novo Nordisk A/S scored higher than 91% of companies evaluated by MarketBeat, and ranked 36th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

Novo Nordisk A/S has received a consensus rating of Hold. The company's average rating score is 2.16, and is based on no strong buy ratings, 4 buy ratings, 14 hold ratings, and 1 sell rating.

Upside Potential

Novo Nordisk A/S has a consensus price target of $64.94, representing about 50.7% upside from its current price of $43.10.

Amount of Analyst Coverage

Novo Nordisk A/S has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -0.87%

Earnings Growth

Earnings for Novo Nordisk A/S are expected to decrease by -0.87% in the coming year, from $3.45 to $3.42 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Novo Nordisk A/S is 10.54, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.09.

Price to Earnings Ratio vs. Sector

The P/E ratio of Novo Nordisk A/S is 10.54, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.94.

Price to Earnings Growth Ratio

Novo Nordisk A/S has a PEG Ratio of 1.50. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Novo Nordisk A/S has a P/B Ratio of 6.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.71% of the float of Novo Nordisk A/S has been sold short.

Short Interest Ratio / Days to Cover

Novo Nordisk A/S has a short interest ratio ("days to cover") of 2.68, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novo Nordisk A/S has recently decreased by 6.44%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Novo Nordisk A/S pays a meaningful dividend of 1.83%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Novo Nordisk A/S does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Novo Nordisk A/S is 20.05%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 23.98% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.62

News Sentiment

Novo Nordisk A/S has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 42 news articles for Novo Nordisk A/S this week, compared to 8 articles on an average week.

Search Interest

76 people have searched for NVO on MarketBeat in the last 30 days. This is an increase of 15% compared to the previous 30 days.

MarketBeat Follows

27 people have added Novo Nordisk A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 59% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.07% of the stock of Novo Nordisk A/S is held by insiders.

Percentage Held by Institutions

11.54% of the stock of Novo Nordisk A/S is held by institutions.

Company Calendar

• Last Earnings: 6/30/2026
• Record date for 8/25 Dividend: 8/17/2026
• Ex-Dividend for 8/25 Dividend: 8/17/2026
• Dividend Payable: 8/25/2026
• Today: 9/11/2026
• CMD 2026: 9/21/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:NVO
• CIK: 353278
• Web: www.novonordisk.com
• Phone: (454) 444-8888
• Fax: 45-4449-0555
• Employees: 69,505
• Year Founded: 1923

Price Target and Rating

• Average Price Target for Novo Nordisk A/S: $64.94
• High Price Target: $175.00
• Low Price Target: $40.00
• Potential Upside/Downside: +50.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.16
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.09
• Trailing P/E Ratio: 10.52
• Forward P/E Ratio: 12.47
• P/E Growth: 1.5
• Net Income: $15.51 billion
• Net Margins: 35.36%
• Pretax Margin: 47.66%
• Return on Equity: 61.20%
• Return on Assets: 21.49%

Debt

• Debt-to-Equity Ratio: 0.59
• Current Ratio: 0.79
• Quick Ratio: 0.56

Sales & Book Value

• Annual Sales: $46.80 billion
• Price / Sales: 4.11
• Cash Flow: $4.53 per share
• Price / Cash Flow: 9.51
• Book Value: $6.58 per share
• Price / Book: 6.54

Miscellaneous

• Outstanding Shares: 4,465,000,000
• Free Float: 4,461,875,000
• Market Cap: $192.15 billion
• Optionable: Optionable
• Beta: 0.74